Radioactive tracer could spot hidden breast cancer tumors
NCT ID NCT06745804
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This early-phase trial is testing a new radioactive imaging agent called 68Ga-R10602 in 36 people with hormone receptor-positive breast cancer that has come back or spread. The agent is designed to light up tumors on PET/CT scans. The main goals are to check safety and see how well it finds cancer locations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE BREAST ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvin and Bren Simon Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UCLA Department of Medicine - Hematology/Oncology
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Michigan Medicine
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Utah, Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 844112, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-R10602 (a radioactive imaging agent injected into the body to find breast cancer tumors on PET/CT scans)
What this could lead to
If successful, this could provide a new way to see where hormone receptor-positive breast cancer has spread, helping doctors plan better treatment.
What could go wrong
This is a very early Phase 1 study with only 36 people, focused on safety and imaging ability, not treatment. The imaging agent may not work as hoped or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.